ALK and neoplasm: Choi et al. described two different secondary mutations in the kinase domain of EML4-ALK in tumor cells isolated from a crizotinib-refractory patient [35], one of which was the gatekeeper mutation L1196M, which corresponds to T315I in BCR-ABL and T790M in EGFR.